- The FDA has granted emergency use authorization (EUA) to Qiagen N.V.’s (NYSE:QGEN) QIAreach SARS CoV-2 Antigen Test.
- The rapid, portable test can detect COVID-19 antigen in people with active infections in 2 to 15 minutes.
- The test can process an average of around 30 swab samples per hour, providing digital test results that do not require subjective interpretation.
- The QIAreach test is the second Qiagen COVID-19 test to use the digital eHub and eStick system developed in partnership with Australian digital diagnostics company, Ellume.
- Lab professionals will now be able to run tests to detect both previous and active infections on one device simultaneously, with each testing slot operating independently of the others.
- Each Digital eHub device, with a capacity for up to 8 eSticks, can simultaneously run QIAreach COVID-19 antigen and antibody tests.
- Related: Qiagen Stock Gains As Non-COVID Sales Boosts Q2 Topline, Bottom-line.
- Price Action: QGEN shares closed down 0.72% at $52.36 on Friday.
- Related content: Benzinga’s Full FDA Calendar.
- Photo by Mufid Majnun on Unsplash
ETF BAD Debuts With A Focus On Cannabis Stocks, Gambling And Alcohol
Listed Funds Trust is debuting the BAD ETF (BAD) on Wednesday to target an index focused on gambling, alcohol and cannabis stocks, reported Bloomberg.
